You're getting them confused. Read your own link, page 17: 4.4.1.2. Monitoring for Safety
Efficacy is reviewed in monitoring for safety; they just won't report it out.
The quote you provided from the CEO is one with him saying that they will not report out interim data. DSMC is still reviewing for safety (which includes efficacy).
The people in the know have the data and the bio stat already made some research on the data in order to find out safety...be sure they know what's going on. If they see dec or Jan get to 189 the trial won't be stopped earlier but if the delay is bigger they won't wait until April for the 189 and stop it early . It's already obvious to u primary endpoint met . Do u think it's not obvious to people who see the data? Like u with no calculations ? Of course it's obvious to them too
News 
Market Data 
Discover 
